Interferon and Alternative Activation of Monocyte/Macrophages in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

被引:110
|
作者
Christmann, Romy B. [2 ]
Hayes, Everett
Pendergrass, Sarah [3 ,4 ]
Padilla, Cristina
Farina, Giuseppina
Affandi, Alsya J. [5 ]
Whitfield, Michael L. [4 ]
Farber, Harrison W.
Lafyatis, Robert [1 ]
机构
[1] Boston Univ, Sch Med, Arthrit Ctr E501, Boston, MA 02118 USA
[2] Univ Sao Paulo, Sao Paulo, Brazil
[3] Vanderbilt Univ, Nashville, TN USA
[4] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA
[5] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
来源
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 06期
关键词
RECEPTORS; MONOCYTES; THICKNESS; THERAPY; DISEASE; PROTEIN; MARKER; ALPHA; CELLS; SCORE;
D O I
10.1002/art.30318
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To explore the relationship between biomarkers of pulmonary arterial hypertension (PAH), interferon (IFN)-regulated gene expression, and the alternative activation pathway in systemic sclerosis (SSc). Methods. Peripheral blood mononuclear cells (PBMCs) were purified from healthy controls, patients with idiopathic PAH, and SSc patients (classified as having diffuse cutaneous SSc, limited cutaneous SSc [lcSSc] without PAH, and lcSSc with PAH). IFN-regulated and "PAH biomarker" genes were compared after supervised hierarchical clustering. Messenger RNA levels of selected IFN-regulated genes (Siglec1 and MX1), biomarker genes (IL13RA1, CCR1, and JAK2), and the alternative activation marker gene (MRC1) were analyzed on PBMCs and on CD14- and CD14+ cell populations. Interleukin-13 (IL-13) and IL-4 concentrations were measured in plasma by immunoassay. CD14, MRC1, and IL13RA1 surface expression was analyzed by flow cytometry. Results. Increased PBMC expression of both IFN-regulated and biomarker genes distinguished SSc patients from healthy controls. Expression of genes in the biomarker cluster, but not in the IFN-regulated cluster, distinguished lcSSc with PAH from lcSSc without PAH. The genes CCR1 (P < 0.001) and JAK2 (P < 0.001) were expressed more highly in lcSSc patients with PAH compared with controls and mainly by CD14+ cells. MRC1 expression was increased exclusively in lcSSc patients with PAH (P < 0.001) and correlated strongly with pulmonary artery pressure (r = 0.52, P = 0.03) and higher mortality (P = 0.02). MRC1 expression was higher in CD14+ cells and was greatly increased by stimulation with IL-13. IL-13 concentrations in plasma were most highly increased in lcSSc patients with PAH (P < 0.001). Conclusion. IFN-regulated and biomarker genes represent distinct, although related, clusters in lcSSc patients with PAH. MRC1, a marker for the effect of IL-13 on alternative monocyte/macrophage activation, is associated with this severe complication and is related to mortality.
引用
收藏
页码:1718 / 1728
页数:11
相关论文
共 50 条
  • [1] Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
    Chaisson, Neal F.
    Hassoun, Paul M.
    CHEST, 2013, 144 (04) : 1346 - 1356
  • [2] Systemic Sclerosis-associated Pulmonary Arterial Hypertension
    Le Payec, Jerome
    Humbert, Marc
    Mouthon, Luc
    Hassoun, Paul M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (12) : 1285 - 1293
  • [3] Systemic sclerosis-associated pulmonary arterial hypertension in children
    Apitz, Christian
    Girschick, Hermann
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2021, 11 (04) : 1137 - 1143
  • [4] Update in systemic sclerosis-associated pulmonary arterial hypertension
    Gashouta, Mohamed A.
    Humbert, Marc
    Hassoun, Paul M.
    PRESSE MEDICALE, 2014, 43 (10): : E293 - E304
  • [5] Risk Assessment in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
    Boucly, A.
    Weatherald, J. C.
    Chaouat, A.
    Cottin, V.
    Dromer, C.
    Hachulla, E.
    Jais, X.
    Jevnikar, M.
    Launay, D.
    Magro, P.
    Montani, D.
    Mouthon, L.
    Pison, C.
    Prevot, G.
    Savale, L.
    Simonneau, G.
    Humbert, M.
    Sitbon, O.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [6] A Molecular Biomarker For Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
    Christmann, R. B.
    Moll, M.
    Whitfield, M. L.
    Wang, Y.
    Rice, L.
    Stratton, E.
    Lafyatis, R.
    Farber, H. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [7] Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
    Roos, Adrienne M.
    Pasarikovski, Christopher
    Kron, Amie T.
    Granton, John T.
    Lee, Peter
    Thenganatt, John
    Johnson, Sindhu R.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1099 - S1099
  • [8] EPOPROSTENOL RESCUE THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION AND IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
    Roos, A. M.
    Pasarikovski, C. R.
    Kron, A.
    Granton, J. T.
    Lee, P.
    Thenganatt, J.
    Johnson, S. R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S86 - S87
  • [9] Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension
    Wuttge, Dirk M.
    Carlsen, Anting L.
    Teku, Gabriel
    Wildt, Marie
    Radegran, Goran
    Vihinen, Mauno
    Heegaard, Niels H. H.
    Hesselstrand, Roger
    RHEUMATOLOGY, 2022, 61 (01) : 309 - 318
  • [10] The expression profiling of microRNA in systemic sclerosis-associated pulmonary arterial hypertension
    Huang, Yu-Xia
    Li, Fei
    Liu, Dong
    Sun, Yuan-Yuan
    Zhao, Qin-Hua
    Jiang, Rong
    Wang, Lan
    Yuan, Ping
    Liu, Jin-Ming
    Wu, Yue
    Zhang, Ji
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (18)